



Notice of Ceasing to be a Substantial Holder

Sydney, Australia and San Diego, California (Friday, 10 June 2016 AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) was notified today by Medtronic, Inc., an affiliate of Medtronic plc, that over the course of the last several months, Medtronic has sold 9,032,185 CDIs (equivalent to 903,220 shares of common stock) of its holdings in REVA. Following these sales, Medtronic maintains approximately two-thirds of its previous investment, continuing to hold a total of 13,526,095 CDIs (equivalent to 1,352,609 shares of common stock) and 379,651 shares of common stock (equivalent to 3,796,510 CDIs), which represents an approximate 4.06 percent remaining ownership stake in REVA.

REVA believes the selling was part of a Medtronic corporate portfolio balancing effort. Medtronic has confirmed that the sales were not related to REVA’s recently released clinical results, that sales have ceased, and that there are no current plans to resume selling.

Please see the attached Form 605 “Notice of ceasing to be a substantial holder” detailing the trades.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds.” The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the *Fantom*[®] scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize *Fantom* or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 10, 2016, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States**Investor & Media Enquiries:**

REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia**Investor Enquiries:**

Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia**Media Enquiries:**

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

For personal use only

Form 605

**Corporations Act 2001
Section 671B**

Notice of ceasing to be a substantial holder

To Company Name/Scheme Reva Medical, Inc.

ACN/ARSN ARBN 146 505 777

1. Details of substantial holder (1)

Name Medtronic, Inc.

ACN/ARSN (if applicable) N/A

The holder ceased to be a substantial holder on 6 / 06 / 2016

The previous notice was given to the company on 16 / 02 / 2016

The previous notice was dated 16 / 02 / 2016

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected*
Refer to Annexure A					

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

4 Addresses

The addresses of persons named in this form are as follows:

Name	Address
Medtronic, Inc.	710 Medtronic Parkway, Minneapolis, MN, 55432-5604, United States
CHESS Depository Nominees Pty Ltd	20 Bridge Street, Sydney, NSW, 2000


For personal use only

Signature

Medtronic, Inc.

By: Peter Shimabukuro, Principal Legal Counsel, as duly authorised representative.

sign here



date

9 / 06 / 2016

For personal use only

Annexure A

This is Annexure A referred to in Form 605, Notice of ceasing to be a substantial holder, dated 9 / 06 / 2016

Signature

Medtronic, Inc.

By: Peter Shimabukuro, Principal Legal Counsel, as duly authorised representative.

sign here

date 9 / 06 / 2016

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5) (\$AUD)	Class (6) and number of securities affected	Person's votes affected*
26/02/2016	Medtronic, Inc.	Disposal of CDIs	55,100.00	50,000 CDIs (equivalent to 5,000 shares of common stock)	5,000
29/02/2016	As above	As above	111,280.00	100,000 (equivalent to 10,000 shares of common stock)	10,000
29/02/2016	As above	As above	95,414.31	84,199 (equivalent to approx 8,420 shares of common stock)	8,420
01/03/2016	As above	As above	91,202.87	80,440 (equivalent to 8,044 shares of common stock)	8,044
2/03/2016	As above	As above	67,902.96	59,564 (equivalent to approx 5,956 shares of common stock)	5,956
3/03/2016	As above	As above	7,410.00	6,500 (equivalent to 650 shares of common stock)	650
4/03/2016	As above	As above	33,414.01	30,100 (equivalent to 3,010 shares of common stock)	3,010
7/03/2016	As above	As above	11,255.00	10,000 (equivalent to 1,000 shares of common stock)	1,000
8/03/2016	As above	As above	201,708.00	180,000 (equivalent to 18,000 shares of common stock)	18,000
9/03/2016	As above	As above	9,412.90	8,330 (equivalent to 833 shares of common stock)	833
10/03/2016	As above	As above	189,763.82	170,943 (equivalent to approx 17,094 shares of common stock)	17,094
11/03/2016	As above	As above	94,787.84	85,356 (equivalent to approx 8,536 shares of common stock)	8,536
15/03/2016	As above	As above	22,000.00	20,000 (equivalent to 2,000 shares of common stock)	2,000
16/03/2016	As above	As above	4,200.00	3,750 (equivalent to 375 shares of common stock)	375
17/03/2016	As above	As above	149,716.60	136,106 (equivalent to approx 13,611 shares of common stock)	13,611

For personal use only

				common stock)	
18/03/2016	As above	As above	12,016.48	10,729 (equivalent to approx 1,073 shares of common stock)	1,073
21/03/2016	As above	As above	7,040.00	6,400 (equivalent to 640 shares of common stock)	640
22/03/2016	As above	As above	25,463.90	23,149 (equivalent to approx 2,315 shares of common stock)	2,315
29/03/2016	As above	As above	89,775.44	80,480 (equivalent to 8,048 shares of common stock)	8,048
30/03/2016	As above	As above	10,304.00	9,200 (equivalent to 920 shares of common stock)	920
31/03/2016	As above	As above	34,600.00	31,250 (equivalent to 3,125 shares of common stock)	3,125
4/04/2016	As above	As above	12,947.00	11,770 (equivalent to 1,177 shares of common stock)	1,177
6/04/2016	As above	As above	11,000.00	10,000 (equivalent to 1,000 shares of common stock)	1,000
7/04/2016	As above	As above	8,600.90	7,819 (equivalent to approx 782 shares of common stock)	782
19/04/2016	As above	As above	7,965.90	7,515 (equivalent to approx 752 shares of common stock)	752
20/04/2016	As above	As above	5,250.00	5,000 (equivalent to 500 shares of common stock)	500
26/04/2016	As above	As above	240,822.12	239,624 (equivalent to approx 23,962 shares of common stock)	23,962
27/04/2016	As above	As above	55,254.00	55,254 (equivalent to approx 5,525 shares of common stock)	5,525
28/04/2016	As above	As above	433,289.33	422,474 (equivalent to approx 42,247 shares of common stock)	42,247
29/04/2016	As above	As above	643,920.00	600,000 (equivalent to 60,000 shares of common stock)	60,000
2/05/2016	As above	As above	23,398.10	21,271 (equivalent to approx 2,127 shares of common stock)	2,127
4/05/2016	As above	As above	234,461.40	219,000 (equivalent to 21,900 shares of common stock)	21,900
5/05/2016	As above	As above	8,774.00	8,200 (equivalent to 820 shares of common stock)	820
6/05/2016	As above	As above	220,420.00	206,000 (equivalent to 20,600 shares of common stock)	20,600
9/05/2016	As above	As above	736,610.00	700,000 (equivalent to 70,000 shares of common stock)	70,000

10/05/2016	As above	As above	690,921.61	657,770 (equivalent to 65,777 shares of common stock)	65,777
11/05/2016	As above	As above	1,065,600.00	1,000,000 (equivalent to 100,000 shares of common stock)	100,000
12/05/2016	As above	As above	1,070,400.00	1,000,000 (equivalent to 100,000 shares of common stock)	100,000
13/05/2016	As above	As above	818,335.72	743,536 (equivalent to approx 74,354 shares of common stock)	74,354
16/05/2016	As above	As above	170,610.00	155,100 (equivalent to 15,510 shares of common stock)	15,510
17/05/2016	As above	As above	25,850.00	23,500 (equivalent to 2,350 shares of common stock)	2,350
18/05/2016	As above	As above	326,621.49	266,521 (equivalent to approx 26,652 shares of common stock)	26,652
19/05/2016	As above	As above	240,353.24	203,207 (equivalent to approx 20,321 shares of common stock)	20,321
20/05/2016	As above	As above	801,253.30	695,110 (equivalent to 69,511 shares of common stock)	69,511
26/05/2016	As above	As above	57,297.07	50,265 (equivalent to approx 5,027 shares of common stock)	5,027
27/05/2016	As above	As above	254,141.01	229,245 (equivalent to approx 22,925 shares of common stock)	22,925
30/05/2016	As above	As above	66,180.00	60,000 (equivalent to 6,000 shares of common stock)	6,000
31/05/2016	As above	As above	49,241.79	44,418 (equivalent to approx 4,442 shares of common stock)	4,442
1/06/2016	As above	As above	209,380.00	190,000 (equivalent to 19,000 shares of common stock)	19,000
2/06/2016	As above	As above	14,408.16	13,090 (equivalent to 1,309 shares of common stock)	1,309

* voting power is calculated on the basis that CDIs were held as shares of common stock. Each share of common stock represents 10 CDIs.